Cdk2 Inhibitor IV, NU6140 is a highly cell-permeable purine compound that displays anticancer properties and acts as a selective and ATP-competitive inhibitor of Cdks (IC50 = 6.6 μM, 0.41 μM, 5.5 μM, 15 μM and 3.9 μM for Cdc2 (Cdk1)/cyclin B, Cdk2/cyclin A, Cdk4/cyclin D, Cdk5/p25 and Cdk7/cyclin H, respectively). Cdk2 Inhibitor IV, NU6140 has been shown to cause cell cycle arrest at the G2/M phase and induce apoptosis by activating caspases and down-regulating survivin. Cdk2 Inhibitor IV, NU6140 has also been shown to synergistically potentiate paclitaxel cytotoxicity and apoptotic response in HeLa and OAW42 cells.
1. Pennati, M., et al. 2005. Mol. Cancer Ther. 4: 1328-1337. PMID: 16170024
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn